SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Emily Dickinson Synthetic CCD

PatientEmily Dickinson
Date of birth1971-12-10
IdentifiersMRN HR-NI023-SYN; SSN (made up) 000-23-6081
Document date2026-11-01
AuthorLucinda Hartwell, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Reason for Visit

Primary care home visit for headaches, nausea, and tiredness, with raised blood pressure and abnormal kidney tests. Concerns: Headaches, nausea, and tiredness for several months, worse in the mornings; Wants her care at home or by video, with as few trips to the clinic as possible. [S]

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Medications

MedicationFrequencyRouteDatesStatusEvidence
Naproxen sodium 220 mg oral tablet, two tablets by mouth as needed for headache (over the counter)Two tablets as needed, up to twice a dayOral route2025-10-01 to 2026-01-12stoppedS
Losartan 50 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-01-12 to 2026-02-02completedS
Losartan 100 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-02-02activeS
Atorvastatin 20 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-01-12activeS
Cholecalciferol (vitamin D3) 25 mcg (1,000 units) oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-01-12activeS
Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for headache, no more than 3 g a dayTwo tablets every 6 hours as needed; maximum 6 tablets a dayOral route2026-01-12activeS
Dapagliflozin 10 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-02-02activeS
Amlodipine 5 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-03-02activeS

Procedures

ProcedureDatesStatusEvidence
12-lead electrocardiogram at the home visit: sinus rhythm, borderline voltage criteria for left ventricular hypertrophy2026-01-12 to 2026-01-12completedS
Kidney ultrasound: right kidney 10.1 cm, left 10.3 cm, with mildly increased cortical echogenicity; no hydronephrosis, stones, or cysts; bladder normal2026-02-02 to 2026-02-02completedS
Advance care planning conversation, about 20 minutes2026-10-19 to 2026-10-19completedS

Immunizations

DateVaccineStatusEvidence
2025-10-20Influenza vaccine, 2025-2026 seasoncompletedS
2019-05-14Tdap vaccinecompletedS
2026-01-12Pneumococcal conjugate vaccine PCV20, given at the home visitcompletedS
2026-06-01Hepatitis B vaccine, CpG-adjuvanted (HepB-CpG), dose 1 of 2completedS
2026-10-19Hepatitis B vaccine, CpG-adjuvanted (HepB-CpG), dose 2 of 2completedS
2026-10-19Influenza vaccine, 2026-2027 seasoncompletedS
2026-10-19Recombinant zoster vaccine, dose 1 of 2completedS

Past Medical History

Historical biography with true dates. These events are not part of the synthetic care timeline.

Historical dateHistoryEvidence
Late winter of 1848Lung congestion and cough; removed from her seminary for about a monthD (CLM-0002)
1851Symptoms then thought to be consumptive, treated with a glycerine prescription for about two years until they subsided; no tuberculosis diagnosis is documentedD (CLM-0003)
1863 to 1865Eye affliction with sensitivity to light and aching eyes, treated by a Boston ophthalmologist with dim light and no reading during two long stays in Cambridgeport; apparently cured. The diagnosis is not recorded (iritis most often proposed)R (CLM-0004, CLM-0005, CLM-0006)
October 1883Nervous prostration after a death in her family, followed by continuing ill healthD (CLM-0010)

Family History

No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.

Health Concerns

ConcernStatusEvidence
Headaches, nausea, and tiredness for several months, worse in the morningsactiveS
Wants her care at home or by video, with as few trips to the clinic as possibleactiveS

Assessment

Most recent measures: Sodium [Moles/volume] in Serum or Plasma 136 on 2026-04-20; Potassium [Moles/volume] in Serum or Plasma 5.3 on 2026-04-20; Carbon dioxide, total [Moles/volume] in Serum or Plasma 20 on 2026-04-20; Urea nitrogen [Mass/volume] in Serum or Plasma 34 on 2026-04-20; Creatinine [Mass/volume] in Serum or Plasma 1.66 on 2026-04-20; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 36 on 2026-04-20; Glucose [Mass/volume] in Serum or Plasma 86 on 2026-04-20; Calcium [Mass/volume] in Serum or Plasma 9.4 on 2026-09-28; Phosphate [Mass/volume] in Serum or Plasma 3.6 on 2026-09-28; Parathyrin.intact [Mass/volume] in Serum or Plasma 61 on 2026-09-28; 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma 36 on 2026-09-28; Albumin [Mass/volume] in Serum or Plasma 4.1 on 2026-01-12; Hemoglobin [Mass/volume] in Blood 12.3 on 2026-01-12; Cholesterol [Mass/volume] in Serum or Plasma 214 on 2026-01-12; Cholesterol in HDL [Mass/volume] in Serum or Plasma 54 on 2026-01-12; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 134 on 2026-01-12; Triglyceride [Mass/volume] in Serum or Plasma 130 on 2026-01-12; Hemoglobin A1c/Hemoglobin.total in Blood 5.5 on 2026-01-12; Thyrotropin [Units/volume] in Serum or Plasma 2.1 on 2026-01-12; Albumin/Creatinine [Mass Ratio] in Urine 96 on 2026-09-28; Erythrocytes [#/area] in Urine sediment by Microscopy high power field 1 on 2026-01-12; Kidney failure 2-year risk [Likelihood] by KFRE 0.5 on 2026-01-12; Kidney failure 5-year risk [Likelihood] by KFRE 1.6 on 2026-01-12; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 3 on 2026-06-01; Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] 3 on 2026-10-19; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 on 2026-10-19; Total score [AUDIT-C] 0 on 2026-10-19 [S]

Strengths and supports: Supports: her household, a few close friends she writes to often, and her work [S]

Problems

ProblemClinical statusVerificationCodeProvenance
Chronic kidney disease stage G3a A2, attributed to hypertension; synthetic modern diagnosis linked to the Bright's disease entered on her death certificateactiveconfirmed N18.31S — Synthetic modern diagnosis. Bright's disease as her recorded cause of death is documented (D); what it meant in her case is a retrospective question (R), and no kidney test from her lifetime exists.
Hypertension with chronic kidney disease (hypertensive chronic kidney disease, stage 3a); synthetic modern diagnosis linked to the retrospective view that she had severe hypertensionactiveconfirmed I12.9S — Synthetic modern diagnosis; severe hypertension is a retrospective interpretation (R, possible), and no blood pressure from her lifetime exists.
Vitamin D deficiency with a mildly raised PTH in chronic kidney diseaseactiveconfirmed E55.9S — Synthetic laboratory finding at the intake visit.
Viral gastroenteritis with volume depletion and a prerenal rise in creatinine while taking losartan and dapagliflozin; resolvedresolvedconfirmed A08.4S — Synthetic illness at an unscheduled home visit, chosen to teach sick-day rules in chronic kidney disease; it does not echo any documented illness.

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-01-12Sodium [Moles/volume] in Serum or Plasma139mmol/L135-145 mmol/LNormalS
2026-01-12Potassium [Moles/volume] in Serum or Plasma4.4mmol/L3.5-5.1 mmol/LNormalS
2026-01-12Carbon dioxide, total [Moles/volume] in Serum or Plasma24mmol/L22-29 mmol/LNormalS
2026-01-12Urea nitrogen [Mass/volume] in Serum or Plasma21mg/dL6-21 mg/dLNormalS
2026-01-12Creatinine [Mass/volume] in Serum or Plasma1.2mg/dL0.59-1.04 mg/dLHighS
2026-01-12Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M54mL/min/{1.73_m2}>=60 mL/min/1.73 m²LowS
2026-01-12Glucose [Mass/volume] in Serum or Plasma92mg/dL70-99 mg/dLNormalS
2026-01-12Calcium [Mass/volume] in Serum or Plasma9.3mg/dL8.6-10.3 mg/dLNormalS
2026-01-12Phosphate [Mass/volume] in Serum or Plasma3.8mg/dL2.5-4.5 mg/dLNormalS
2026-01-12Parathyrin.intact [Mass/volume] in Serum or Plasma74pg/mL15-65 pg/mLHighS
2026-01-1225-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma21ng/mL30-100 ng/mLLowS
2026-01-12Albumin [Mass/volume] in Serum or Plasma4.1g/dL3.5-5 g/dLNormalS
2026-01-12Hemoglobin [Mass/volume] in Blood12.3g/dL12-15.5 g/dLNormalS
2026-01-12Cholesterol [Mass/volume] in Serum or Plasma214mg/dL<=199 mg/dLHighS
2026-01-12Cholesterol in HDL [Mass/volume] in Serum or Plasma54mg/dL>=50 mg/dLNormalS
2026-01-12Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation134mg/dL<=99 mg/dLHighS
2026-01-12Triglyceride [Mass/volume] in Serum or Plasma130mg/dL<=149 mg/dLNormalS
2026-01-12Hemoglobin A1c/Hemoglobin.total in Blood5.5%<=5.6%NormalS
2026-01-12Thyrotropin [Units/volume] in Serum or Plasma2.1m[IU]/L0.4-4 mIU/LNormalS
2026-01-12Albumin/Creatinine [Mass Ratio] in Urine240mg/g<=30 mg/gHighS
2026-01-12Erythrocytes [#/area] in Urine sediment by Microscopy high power field1/[HPF]<=2 /[HPF]NormalS
2026-01-12Kidney failure 2-year risk [Likelihood] by KFRE0.5%S
2026-01-12Kidney failure 5-year risk [Likelihood] by KFRE1.6%S
2026-01-12Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]6{score}S
2026-01-12Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]5{score}S
2026-02-02Sodium [Moles/volume] in Serum or Plasma140mmol/L135-145 mmol/LNormalS
2026-02-02Potassium [Moles/volume] in Serum or Plasma4.6mmol/L3.5-5.1 mmol/LNormalS
2026-02-02Carbon dioxide, total [Moles/volume] in Serum or Plasma24mmol/L22-29 mmol/LNormalS
2026-02-02Urea nitrogen [Mass/volume] in Serum or Plasma22mg/dL6-21 mg/dLHighS
2026-02-02Creatinine [Mass/volume] in Serum or Plasma1.26mg/dL0.59-1.04 mg/dLHighS
2026-02-02Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M51mL/min/{1.73_m2}>=60 mL/min/1.73 m²LowS
2026-02-02Glucose [Mass/volume] in Serum or Plasma90mg/dL70-99 mg/dLNormalS
2026-02-02Albumin/Creatinine [Mass Ratio] in Urine262mg/g<=30 mg/gHighS
2026-03-02Sodium [Moles/volume] in Serum or Plasma139mmol/L135-145 mmol/LNormalS
2026-03-02Potassium [Moles/volume] in Serum or Plasma4.8mmol/L3.5-5.1 mmol/LNormalS
2026-03-02Carbon dioxide, total [Moles/volume] in Serum or Plasma23mmol/L22-29 mmol/LNormalS
2026-03-02Urea nitrogen [Mass/volume] in Serum or Plasma23mg/dL6-21 mg/dLHighS
2026-03-02Creatinine [Mass/volume] in Serum or Plasma1.32mg/dL0.59-1.04 mg/dLHighS
2026-03-02Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M48mL/min/{1.73_m2}>=60 mL/min/1.73 m²LowS
2026-03-02Glucose [Mass/volume] in Serum or Plasma88mg/dL70-99 mg/dLNormalS
2026-06-01Sodium [Moles/volume] in Serum or Plasma140mmol/L135-145 mmol/LNormalS
2026-06-01Potassium [Moles/volume] in Serum or Plasma4.7mmol/L3.5-5.1 mmol/LNormalS
2026-06-01Carbon dioxide, total [Moles/volume] in Serum or Plasma24mmol/L22-29 mmol/LNormalS
2026-06-01Urea nitrogen [Mass/volume] in Serum or Plasma22mg/dL6-21 mg/dLHighS
2026-06-01Creatinine [Mass/volume] in Serum or Plasma1.3mg/dL0.59-1.04 mg/dLHighS
2026-06-01Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M49mL/min/{1.73_m2}>=60 mL/min/1.73 m²LowS
2026-06-01Glucose [Mass/volume] in Serum or Plasma91mg/dL70-99 mg/dLNormalS
2026-06-01Albumin/Creatinine [Mass Ratio] in Urine118mg/g<=30 mg/gHighS
2026-06-01Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]3{score}S
2026-09-28Sodium [Moles/volume] in Serum or Plasma139mmol/L135-145 mmol/LNormalS
2026-09-28Potassium [Moles/volume] in Serum or Plasma4.6mmol/L3.5-5.1 mmol/LNormalS
2026-09-28Carbon dioxide, total [Moles/volume] in Serum or Plasma25mmol/L22-29 mmol/LNormalS
2026-09-28Urea nitrogen [Mass/volume] in Serum or Plasma21mg/dL6-21 mg/dLNormalS
2026-09-28Creatinine [Mass/volume] in Serum or Plasma1.28mg/dL0.59-1.04 mg/dLHighS
2026-09-28Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M50mL/min/{1.73_m2}>=60 mL/min/1.73 m²LowS
2026-09-28Glucose [Mass/volume] in Serum or Plasma90mg/dL70-99 mg/dLNormalS
2026-09-28Albumin/Creatinine [Mass Ratio] in Urine96mg/g<=30 mg/gHighS
2026-09-28Calcium [Mass/volume] in Serum or Plasma9.4mg/dL8.6-10.3 mg/dLNormalS
2026-09-28Phosphate [Mass/volume] in Serum or Plasma3.6mg/dL2.5-4.5 mg/dLNormalS
2026-09-28Parathyrin.intact [Mass/volume] in Serum or Plasma61pg/mL15-65 pg/mLNormalS
2026-09-2825-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma36ng/mL30-100 ng/mLNormalS
2026-04-20Sodium [Moles/volume] in Serum or Plasma136mmol/L135-145 mmol/LNormalS
2026-04-20Potassium [Moles/volume] in Serum or Plasma5.3mmol/L3.5-5.1 mmol/LHighS
2026-04-20Carbon dioxide, total [Moles/volume] in Serum or Plasma20mmol/L22-29 mmol/LLowS
2026-04-20Urea nitrogen [Mass/volume] in Serum or Plasma34mg/dL6-21 mg/dLHighS
2026-04-20Creatinine [Mass/volume] in Serum or Plasma1.66mg/dL0.59-1.04 mg/dLHighS
2026-04-20Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M36mL/min/{1.73_m2}>=60 mL/min/1.73 m²LowS
2026-04-20Glucose [Mass/volume] in Serum or Plasma86mg/dL70-99 mg/dLNormalS
2026-10-19Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]0{score}S
2026-10-19Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]3{score}S
2026-10-19Total score [AUDIT-C]0{score}S

Social History

Vital Signs

DateMeasureValueUnitProvenance
2026-01-12Body height163cmS
2026-01-12Body weight54kgS
2026-01-12Body mass index (BMI) [Ratio]20.3kg/m2S
2026-01-12Systolic blood pressure166mm[Hg]S
2026-01-12Diastolic blood pressure98mm[Hg]S
2026-01-12Heart rate78/minS
2026-01-12Respiratory rate14/minS
2026-01-12Body temperature36.6CelS
2026-01-12Oxygen saturation in Arterial blood by Pulse oximetry98%S
2026-02-02Body height163cmS
2026-02-02Body weight53.8kgS
2026-02-02Body mass index (BMI) [Ratio]20.2kg/m2S
2026-02-02Systolic blood pressure148mm[Hg]S
2026-02-02Diastolic blood pressure88mm[Hg]S
2026-02-02Heart rate74/minS
2026-02-02Respiratory rate14/minS
2026-02-02Body temperature36.5CelS
2026-02-02Oxygen saturation in Arterial blood by Pulse oximetry98%S
2026-03-02Body height163cmS
2026-03-02Body weight53.6kgS
2026-03-02Body mass index (BMI) [Ratio]20.2kg/m2S
2026-03-02Systolic blood pressure136mm[Hg]S
2026-03-02Diastolic blood pressure84mm[Hg]S
2026-03-02Heart rate72/minS
2026-03-02Respiratory rate14/minS
2026-03-02Body temperature36.6CelS
2026-03-02Oxygen saturation in Arterial blood by Pulse oximetry98%S
2026-04-20Body height163cmS
2026-04-20Body weight51.9kgS
2026-04-20Body mass index (BMI) [Ratio]19.5kg/m2S
2026-04-20Systolic blood pressure104mm[Hg]S
2026-04-20Diastolic blood pressure64mm[Hg]S
2026-04-20Heart rate102/minS
2026-04-20Respiratory rate18/minS
2026-04-20Body temperature37.6CelS
2026-04-20Oxygen saturation in Arterial blood by Pulse oximetry97%S
2026-06-01Body height163cmS
2026-06-01Body weight53.2kgS
2026-06-01Body mass index (BMI) [Ratio]20kg/m2S
2026-06-01Systolic blood pressure124mm[Hg]S
2026-06-01Diastolic blood pressure76mm[Hg]S
2026-06-01Heart rate70/minS
2026-06-01Respiratory rate14/minS
2026-06-01Body temperature36.6CelS
2026-06-01Oxygen saturation in Arterial blood by Pulse oximetry98%S
2026-09-28Body height163cmS
2026-09-28Body weight53.4kgS
2026-09-28Body mass index (BMI) [Ratio]20.1kg/m2S
2026-09-28Systolic blood pressure118mm[Hg]S
2026-09-28Diastolic blood pressure74mm[Hg]S
2026-09-28Heart rate68/minS
2026-09-28Respiratory rate14/minS
2026-09-28Body temperature36.5CelS
2026-09-28Oxygen saturation in Arterial blood by Pulse oximetry98%S
2026-10-19Body height163cmS
2026-10-19Body weight53.5kgS
2026-10-19Body mass index (BMI) [Ratio]20.1kg/m2S
2026-10-19Systolic blood pressure120mm[Hg]S
2026-10-19Diastolic blood pressure74mm[Hg]S
2026-10-19Heart rate70/minS
2026-10-19Respiratory rate14/minS
2026-10-19Body temperature36.6CelS
2026-10-19Oxygen saturation in Arterial blood by Pulse oximetry98%S

Encounters

DatePurposeStatusProvenance
2026-01-12Primary care home visit for headaches, nausea, and tiredness, with raised blood pressure and abnormal kidney testsfinishedS
2026-02-02Three-week kidney and blood pressure review in the clinic, combined with nephrology consultation and kidney ultrasound on one tripfinishedS
2026-03-02Video visit four weeks after the losartan increase and dapagliflozin start, with home vital signs and home blood testsfinishedS
2026-04-20Same-day home sick visit for vomiting and diarrheafinishedS
2026-06-01Home visit for the three-month kidney and blood pressure reviewfinishedS
2026-09-28Video visit for the six-month kidney review, with home vital signs and home blood testsfinishedS
2026-10-19Periodic adult preventive visitfinishedS

Plan of Treatment

InterventionStatusGuidelineProvenance
Start losartan 50 mg daily and raise it to the maximum dose of 100 mg for A2 albuminuria; check potassium and creatinine 2 to 4 weeks after each start or increase, accepting a creatinine rise of up to 30 percentcompletedGL-CMID-2026, GL-KDIGO-CKD-2024, GL-KDIGO-BP-2021S
If a second sample confirms a urine albumin-creatinine ratio of at least 200 mg/g, add an SGLT2 inhibitor (dapagliflozin 10 mg daily) after the nephrology review, and check potassium and creatinine 2 to 4 weeks latercompletedGL-CMID-2026, GL-KDIGO-CKD-2024S
Stop naproxen and avoid all NSAIDs; acetaminophen for headache; check kidney function before any iodinated contrast; adjust drug doses to eGFRcompletedGL-CMID-2026, GL-KDIGO-CKD-2024S
Nephrology consultation to confirm the cause of chronic kidney disease with albuminuria in a woman in her fifties and to advise on treatment and follow-upcompletedGL-CMID-2026, GL-KDIGO-CKD-2024S
Sick-day guidance: during vomiting, diarrhea, or poor fluid intake, pause losartan, dapagliflozin, and any other blood pressure medicine, drink fluids, call the clinic, and restart after 24 to 48 hours of normal eating and drinkingcompletedGL-CMID-2026, GL-KDIGO-CKD-2024S
CMID kidney and blood pressure monitoring: blood pressure every visit with home readings; eGFR and urine albumin twice a year at G3a A2; a metabolic panel with each draw; calcium, phosphate, and PTH every 6 to 12 months; vitamin D at baseline; hemoglobin and KFRE yearly; one lipid panel and a statin; medication review every visit; vaccines reviewed yearlycompletedGL-CMID-2026, GL-KDIGO-CKD-2024, GL-ACC-HTN-2017S
Atorvastatin 20 mg daily; vitamin D3 1,000 units daily with recheck of 25-hydroxyvitamin D, calcium, phosphate, and PTHcompletedGL-CMID-2026, GL-KDIGO-CKD-2024S
Vaccines for chronic kidney disease: PCV20 now, a two-dose hepatitis B series, and yearly influenza and COVID-19 vaccinescompletedGL-CMID-2026, GL-KDIGO-CKD-2024, GL-CDC-IMZ-2026S
Home-centered care: home visits and video visits with her own validated blood pressure cuff, scale, thermometer, and pulse oximeter; mobile phlebotomy; clinic trips only for tests that need them, with several tasks booked on one quiet early appointmentcompletedGL-CMID-2026, GL-KDIGO-CKD-2024S
PHQ-9 and GAD-7 at baseline and yearly; her long-standing wish for solitude is respected and not treated as a disorder unless symptoms cause distress or impairmentcompletedGL-CMID-2026, GL-USPSTF-ANX-2023, GL-USPSTF-DEP-2023S
Sodium below 2 g a day, a plant-rich diet, and at least 150 minutes a week of activity, such as garden work and walkingcompletedGL-CMID-2026, GL-KDIGO-CKD-2024, GL-ACC-HTN-2017S

Goals

GoalTargetStatusOutcomeProvenance
Systolic blood pressure below 120 mmHg (KDIGO), and at least below 130/80, without lightheadedness2026-09-28completed118/74 mmHg on losartan 100 mg and amlodipine 5 mgS
Urine albumin-creatinine ratio down by at least 30 percent from baseline on an ARB and an SGLT2 inhibitor2026-06-01completed118 mg/g at three months and 96 mg/g at six months, from 240 mg/gS
Stable kidney function, with no fall in eGFR of more than 20 percent after the expected early dip2026-09-28activeeGFR 50 at the six-month review (54 at baseline); a temporary fall to 36 during gastroenteritis recoveredS
25-hydroxyvitamin D of at least 30 ng/mL2026-09-28completed36 ng/mL on vitamin D3; PTH 61 pg/mLS
Care delivered at home or by video wherever safe, with clinic trips limited to tests that need the clinic2026-09-28completedTwo clinic trips in the episode, each combining several tasks; all other visits at home or by videoS

Functional Status

Mental Status